Many hopes have been pinned on repurposing existing drugs, such as ivermectin and hydroxychloroquine, to treat COVID-19. However, we shouldn’t be too surprised these drugs haven’t yet lived up to the hype. Our study, published today in Science Translational Medicine, shows it’s notoriously difficult to repurpose existing drugs for new diseases or for new uses.
The World Health Organization said Wednesday that ivermectin—touted by some on social media as a COVID-19 “miracle cure”—should not be used to treat coronavirus patients. In response to the swirl of claims around the cheap anti-parasite drug, the WHO issued guidelines saying ivermectin should only be used on COVID-19 patients in clinical trial settings. The
The World Health Organization said Wednesday that ivermectin—touted by some on social media as a COVID-19 “miracle cure”—should not be used to treat coronavirus patients. In response to the swirl of claims around the cheap anti-parasite drug, the WHO issued guidelines saying ivermectin should only be used on COVID-19 patients in clinical trial settings. The
Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network (WWARN)'s new meta-analysis published today provides evidence that supports removing this barrier and improving treatment equity. A systematic review and
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok